Business
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hyp
About this update from Liquidia Corporation
[{"type":"image","alt":"Liquidia Technologies, Inc.","displaySize":"","headline":null,"caption":"Liquidia Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DVUkf7FjeVJYzKXYtdS8kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f","width":300,"height":96}},"lazy":false},{"type":"text","content":"MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with LIQ861, approved in the United States as YUTREPIA™ (treprostinil) inhalation powder, and L606, an investigational extended-release formulation of inhaled treprostinil.","length":738,"tagName":"p"},{"type":"text","content":"Dr. Rajeev Saggar, Liquidia’s Chief Medical Officer, said: “We are pleased to present additional interim data from the open-label ASCENT study evaluating LIQ861in PH-ILD, as well as the 48-week open-label data for L606 in PAH and PH-ILD at PVRI. We are excited for the opportunity to showcase the strength and breadth of our data, and the potential impact it may have for patients and the global medical community.”","length":415,"tagName":"p"},{"type":"text","content":"Title: Safety and Exploratory Efficacy data of LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD patients: ASCENT to Week 24Date and time: Thursday, January 29, 2026, 3:45 – 5:00 p.m. GMT Paper Number: 83Presenting Author: Seth Hall, MBA, RRT, RRT-ACCS, RRT-NPS, Liquidia","length":273,"tagName":"p"},{"type":"text","content":"Title: Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects with Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Inte...